Martin Barrett on Intravenous Versus Subcutaneous Rituximab

Martin Barrett, PhD
Published: Saturday, Jun 20, 2015



Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

In this study, the standard dose of IV rituximab was concentrated 12 fold, to 120 mg/ml and mixed with a naturally occurring enzyme which allows it to be injected at volumes that would otherwise be difficult to administer, says Barrett.

The injection takes only six minutes, compared with a two to four hour infusion. Complete and overall response rates and toxicity were comparable between the two administration methods.

<<< View more from the 13th International Conference on Malignant Lymphoma



Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

In this study, the standard dose of IV rituximab was concentrated 12 fold, to 120 mg/ml and mixed with a naturally occurring enzyme which allows it to be injected at volumes that would otherwise be difficult to administer, says Barrett.

The injection takes only six minutes, compared with a two to four hour infusion. Complete and overall response rates and toxicity were comparable between the two administration methods.

<<< View more from the 13th International Conference on Malignant Lymphoma


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x